Ocular Surface Disease in Thyroid Eye Disease: A Narrative Review

Overview

Journal Ocul Surf

Specialty Ophthalmology

Date 2022 Feb 15

PMID 35167950

Authors

Harkaran S Rana

Sruti S Akella

Carson E Clabeaux

Zachary P Skurski

Vinay K Aakalu

Affiliations

Soon will be listed here.

Abstract

Ocular surface disease (OSD) in the setting of thyroid eye disease (TED) is traditionally thought of as a natural consequence of anatomical changes such as proptosis and corneal exposure. However, a growing body of research suggests that ocular surface inflammation and multi-factorial changes to the homeostasis of the ocular surface contribute substantially to the OSD seen in TED patients. In this paper we review the existing literature which highlights the work and existing theories underlying this new paradigm shift.

Citing Articles

Research progress on the immune mechanism of thyroid-related eye disease combined with dry eye.

Wang Y, Chen D, Jin L, Li D J Ophthalmic Inflamm Infect. 2025; 15(1):23.

PMID: 40063329 PMC: 11893917. DOI: 10.1186/s12348-025-00477-7.

Eyeball descending identification using MRI-based spatial coordinates in thyroid-associated orbitopathy patients with unilateral upper eyelid retraction.

Gou X, Wang Y, Li T, Zhou L, Lian J, Zhang X Quant Imaging Med Surg. 2025; 15(2):1287-1296.

PMID: 39995720 PMC: 11847195. DOI: 10.21037/qims-24-1659.

Ocular surface disease index in Graves' orbitopathy: a cross-sectional study.

Maglionico M, Lanzolla G, Figus M, Cosentino G, Comi S, Marino M Front Endocrinol (Lausanne). 2024; 15:1428185.

PMID: 39713053 PMC: 11659954. DOI: 10.3389/fendo.2024.1428185.

A Comprehensive Review of Thyroid Eye Disease Pathogenesis: From Immune Dysregulations to Novel Diagnostic and Therapeutic Approaches.

Kulbay M, Tanya S, Tuli N, Dahoud J, Dahoud A, Alsaleh F Int J Mol Sci. 2024; 25(21).

PMID: 39519180 PMC: 11546489. DOI: 10.3390/ijms252111628.

Thyroid Eye Disease: Advancements in Orbital and Ocular Pathology Management.

Scarabosio A, Surico P, Singh R, Tereshenko V, Musa M, DEsposito F J Pers Med. 2024; 14(7).

PMID: 39064030 PMC: 11278049. DOI: 10.3390/jpm14070776.

References

Douglas R, Kahaly G, Patel A, Sile S, Thompson E, Perdok R . Teprotumumab for the Treatment of Active Thyroid Eye Disease. N Engl J Med. 2020; 382(4):341-352. DOI: 10.1056/NEJMoa1910434. View

Feldmann M, Brennan F, Chantry D, Haworth C, Turner M, Katsikis P . Cytokine assays: role in evaluation of the pathogenesis of autoimmunity. Immunol Rev. 1991; 119:105-23. DOI: 10.1111/j.1600-065x.1991.tb00580.x. View

Achtsidis V, Tentolouris N, Theodoropoulou S, Panagiotidis D, Vaikoussis E, Saldana M . Dry eye in Graves ophthalmopathy: correlation with corneal hypoesthesia. Eur J Ophthalmol. 2013; 23(4):473-9. DOI: 10.5301/ejo.5000259. View

Tomlinson A, Khanal S, Ramaesh K, Diaper C, McFadyen A . Tear film osmolarity: determination of a referent for dry eye diagnosis. Invest Ophthalmol Vis Sci. 2006; 47(10):4309-15. DOI: 10.1167/iovs.05-1504. View

Craig J, Nichols K, Akpek E, Caffery B, Dua H, Joo C . TFOS DEWS II Definition and Classification Report. Ocul Surf. 2017; 15(3):276-283. DOI: 10.1016/j.jtos.2017.05.008. View

Wu L, Cheng J, Cai J, Le Q, Ma X, Gao L . Observation of Corneal Langerhans Cells by In Vivo Confocal Microscopy in Thyroid-Associated Ophthalmopathy. Curr Eye Res. 2016; 41(7):927-32. DOI: 10.3109/02713683.2015.1133833. View

Armitage W, Mazur P . Osmotic tolerance of human granulocytes. Am J Physiol. 1984; 247(5 Pt 1):C373-81. DOI: 10.1152/ajpcell.1984.247.5.C373. View

Mandic J, Kozmar A, Kusacic-Kuna S, Jazbec A, Mandic K, Mrazovac D . The levels of 12 cytokines and growth factors in tears: hyperthyreosis vs euthyreosis. Graefes Arch Clin Exp Ophthalmol. 2018; 256(4):845-852. DOI: 10.1007/s00417-017-3892-6. View

Park J, Baek S . Dry eye syndrome in thyroid eye disease patients: The role of increased incomplete blinking and Meibomian gland loss. Acta Ophthalmol. 2018; 97(5):e800-e806. DOI: 10.1111/aos.14000. View

10.

Willems F, Marchant A, Delville J, Gerard C, Delvaux A, Velu T . Interleukin-10 inhibits B7 and intercellular adhesion molecule-1 expression on human monocytes. Eur J Immunol. 1994; 24(4):1007-9. DOI: 10.1002/eji.1830240435. View

11.

Kim K, Baek J, Lee S, Lee J, Choi H, Kim S . Causes and Surgical Outcomes of Lower Eyelid Retraction. Korean J Ophthalmol. 2017; 31(4):290-298. PMC: 5540983. DOI: 10.3341/kjo.2016.0059. View

12.

Choi W, Li Y, Ji Y, Yoon K . Oxidative stress markers in tears of patients with Graves' orbitopathy and their correlation with clinical activity score. BMC Ophthalmol. 2018; 18(1):303. PMC: 6249971. DOI: 10.1186/s12886-018-0969-x. View

13.

Cross J, Girkin C, Owsley C, McGwin Jr G . The association between thyroid problems and glaucoma. Br J Ophthalmol. 2008; 92(11):1503-5. PMC: 2708670. DOI: 10.1136/bjo.2008.147165. View

14.

Mak F, Ting M, Edmunds M, Harker A, Edirisinghe M, Duggineni S . Videographic Analysis of Blink Dynamics following Upper Eyelid Blepharoplasty and Its Association with Dry Eye. Plast Reconstr Surg Glob Open. 2020; 8(7):e2991. PMC: 7413808. DOI: 10.1097/GOX.0000000000002991. View

15.

Fang S, Huang Y, Liu X, Zhong S, Wang N, Zhao B . Interaction Between CCR6+ Th17 Cells and CD34+ Fibrocytes Promotes Inflammation: Implications in Graves' Orbitopathy in Chinese Population. Invest Ophthalmol Vis Sci. 2018; 59(6):2604-2614. DOI: 10.1167/iovs.18-24008. View

16.

Marcocci C, Kahaly G, Krassas G, Bartalena L, Prummel M, Stahl M . Selenium and the course of mild Graves' orbitopathy. N Engl J Med. 2011; 364(20):1920-31. DOI: 10.1056/NEJMoa1012985. View

17.

Smith T, Kahaly G, Ezra D, Fleming J, Dailey R, Tang R . Teprotumumab for Thyroid-Associated Ophthalmopathy. N Engl J Med. 2017; 376(18):1748-1761. PMC: 5718164. DOI: 10.1056/NEJMoa1614949. View

18.

Lee H, Roh H, Yoon J, Lee S . Assessment of quality of life and depression in Korean patients with Graves' ophthalmopathy. Korean J Ophthalmol. 2010; 24(2):65-72. PMC: 2851004. DOI: 10.3341/kjo.2010.24.2.65. View

19.

Yilmaz Tugan B, Ozkan B . Evaluation of Meibomian Gland Loss and Ocular Surface Changes in Patients with Mild and Moderate-to-Severe Graves' Ophthalmopathy. Semin Ophthalmol. 2021; 37(3):271-276. DOI: 10.1080/08820538.2021.1937662. View

20.

Saraci G, Treta A . Ocular changes and approaches of ophthalmopathy in basedow - graves- parry- flajani disease. Maedica (Bucur). 2011; 6(2):146-52. PMC: 3239395. View